Penn State Health Milton S. Hershey Medical Center became the second hospital in the nation to implant a newly-designed mechanical pump in a patient with severe heart failure.
In a new multicenter study, researchers led by University of Utah Health physicians report that an emerging heart failure treatment could potentially reverse structural damage to the heart, allowing it to heal itself over time. Overall, 19 (40%) patients who were treated with a combination of LVAD support with heart failure medications had sufficient improvement that the LVAD could be removed.
Travel restrictions imposed to curb the spread of COVID-19 are making it more difficult for some heart failure patients who have artificial heart pumps to participate in follow-up care at implantation centers far from their homes. But a new study suggests there may be a viable alternative.
According to University of Utah Health researchers, local doctors in rural areas who receive specialized training in managing the devices and who work in conjunction with cardiovascular experts at a major medical center can care for these patients safely and effectively.
The 8th annual Utah Cardiac Recovery Symposium (U-CARS) will host thought leaders and noted speakers from around the globe to discuss ground-breaking research in the field of cardiac recovery.
MedStar Heart & Vascular Institute has enrolled its first patient to a clinical trial to determine whether cardiac stem cells reduce inflammation enough to improve heart function in patients with heart failure severe enough to require a left ventricular assist device, or LVAD.
ANN ARBOR, Mich. — Mitral valve procedures are often not performed because of the standing belief that LVAD support resolves mitral regurgitation, due to better left heart performance. A new study in The Journal of Thoracic and Cardiovascular Surgery found when…